Published and Validated

siRNA, HPLC Purified

A llele Biotech’s Published and Validated siRNA are

published and validated siRNA oligos for hundreds of
genes. These siRNA oligos have already been confirmed
Using siRNA
siRNA oligos are delivered freeze dried (5 vials x 40 μg, 5
vials x 3.0 nmole)
to inhibit corresponding gene expression effectively.
Additionaly all siRNA oligos are HPLC purified to ensure 1.) Briefly centrifuge the tube to ensure the dried siRNA is
experimental accuracy. set at the bottom of the tube.
2.) Resuspend siRNA according to the following table for
desired concentration: siRNA (nmole) DEPC H2O (ml)
siRNA Conc. (μM)
General Handling
♦ RNA oligonucleotides are susceptible to degradation by
ribonucleases induced during handling. As a precaution
please wear gloves when handling siRNA.
Box 1 | Resuspension

siRNA DEPC H2O siRNA

♦ RNAse-free reagents, barrier pipette tips, and tubes (nmole) (ml) Conc. (μM)
should be used when working with siRNA.
3 0.15 20
♦ The siRNA is stable when stored in a non-frost-free 6 0.30 20
freezer at - 20°C for one year. 60 1.00 60
120 1.00 120
♦ For long term storage, store the siRNA at -80°C freezer
180 1.00 180
240 1.00 240

Box 2| Product List

Cat. No. Gene (Ref) Accession Position Gene Target

# from (Comments)
ABP-Ri-VAsi-D## ATG
D01 ß-actin NM_001101 972-994 aatgaagatcaagatcattgc
S: TGAAGATCAAGATCATTGCdTdT
AS: GCAATGATCTTGATCTTCAdTdT
D02 gamma-actin NM_001614 8-30 Aagagatcgccgcgctggtca
S: GAGATCGCCGCGCTGGTCAdTdT
AS:
TGACCAGCGCGGCGATCTCdTdT
D03 AIB1 (estrogen AAAGACUCCUUAGGACCGCUU
receptor coactivator)

D04 Apaf-1 978-998 AATTGGTGCACTTTTACGTGA

D05 ARC21 AF006086 181-203 aagaatgaagctgataggacc
D06 ATR interacting AF451323 254-274 AAGGTCCACAGATTATTAGAT
protein
D07 ATR interacting AF451323 464-484 CTAGAGGAACAGAGAAGATCACA
protein

Allele Biotech-Introducing Cost Effectiveness to Research

Box 3| Product List Continued

Cat. No. Gene (Ref) Accession Position Gene Target

# from (Comments)
ABP-Ri-VAsi-D## ATG
D09 Bcr-abl AAGCAGAGUUCAAAAGCCCUU
D10 Brc-abl AAAGCAGAGUUCAAAAGCCCU
D11 beta-tubulin- mouse AF312873 AAGACAGAGCCAAGUGGACUC
neuronal

D12 Bruton's tyrosine NM_000061 1682-1700 AAUUGGUAAACGAUCAAGGAG

kinase (Btk)
D13 Bruton's tyrosine NM_000061 895-913 AAGGGAAAGAAGGAGGUUUCA
kinase (Btk)
D13 Bruton's tyrosine NM_000061 518-536 AAGAAGCUUAAAACCUGGGAG
kinase (Btk)
D14 Casein Kinase I ε 520-538 AACUGGGGAAGAAGGGCAACC
and δ (CKI-ε
and CKI-δ)
D15 Caspase 1 191-211 AAGGGGCACAGGCATGCCAAA

D16 Caspase 2 94-114 AAACAGCTGTTGTTGAGCGAA

D17 hCdc2 125-147

D18 Cdc14A 89-109 GCACAGTAAATACCCACTATT

D19 cdk1 NM_001786 125-147 aaggggttcctagtactgcaa

D20 CENP-E NM_001813 944-966 aaactcttactgctctccagt

D21 CHO1 138-156 AAGGUCAGUAAUACAACGGUG

D22 corin, mouse AACCACCGCCCUCCGUGCA

D23 Cyclin B1 J03166 199-217 CTCGTACAGCCTTGGGAGACA

D24 Cyclin B2 J03167 252-270 ATGTTAAGACTAAGCATGTAC

D25 cytoplasmic dynein 1 U53530 509-531 aaggccaaggaggcgctggaa

heavy chain
D26 DIP13-α (DCC AAGUGCAGCAACACACCUGAC
interacting protein)
D27 DIP13-β (DCC AAGCAGCACCUCUCCUCCCUU
interacting protein)
D28 Dishevelled (hDv-1 and AACAAGATCACCTTCTCCGAG
hDv-3)
D29 hDv-2 AACTTTGAGAACATGAGCAAC

D30 Eg5 NM_004523 1547-1569 aactggatcgtaagaaggcag

D31 emerin NM_000117 628-650 aaccgtgctcctggggctggg

D32 eve AACUCCUUGAACGGCAGCCGC

D33 hFbw7 (cyclin E 713-735 see reference

ubiquitination)
D34 Fortilin 121-141 AAGGUAACAUUGAUGACUCGC

D35 GalTII 65-87 AAGCACGCGACGCUGGCGCGC

(galactosyltransferase II)

Allele Biotech-Introducing Cost Effectiveness to Research

Box 4| Product List Continued

Cat. No. Gene (Ref) Accession Position Gene Target

ABP-Ri-VAsi-D## # from (Comments)
ATG
D36 GalTII 461-482 AAGGCGGACGACGACUCCUUC
(galactosyltransferase II)
D37 GAS41 NM_006530 327-349 aagacctgtaaccctgtatca
D38 Hec-1 NM_006101 1517-1539

D39 HPV E6 AAGAGGUAUAUGACUUUGCUU

D40 HPV E7 AAAGGAGGAUGAAAUAGAUGG

D41 HtrA2 AAAACGGCUCAGGAUUCGUGG

D42 HtrA2 AAGGGGAGTTTGTTGTTGCCA

D43 HtrA2 AAGCTTTCCCGATGTTCAGCA

D44 keratin 18 NM_000224 1154-1176 aagatggcgaggactttaatc

D45 Kinase interacting 160-180 AAGCAGTTCTTGCCGCCAGGA

stathmin (hKIS)
D46 Kinase interacting 160-180 AAGCAGTTCCTGCCTCGGGGA
stathmin (mKIS)
D47 lamin A NM019390 260-280 GAAGCAGCUUCAGGAUGAGAU

D48 lamin A AAGGACCUGGAGGUCUGCUG

D49 lamin A/C NM_005572 608-630 aactggacttccagaagaaca
(90% reduction; 2)
D50 lamin B1 NM_005573 672-694 aacgcgcttggtagaggtgga
D51 lamin B2 M94362 1457-1479 aagaggaggaggaagccgagt

D52 LAP2 NM_003276 37-59 aaagacaagttgaagagtgag

D53 Methyl-CpG-binding AAGCAUGAGCCCGUGCAGCCA
protein 2 (MeCP2)
D54 Methyl-CpG binding AAGAGGAUGGAUUGCCCGGCC
domain protein 2 (MBD2)
D55 Microtubule-associated AAUCCUUCGUCUUUCCUCUCG
protein 2 (MAP2)
D56 Myeloid cell leukemia 456-476 AACCCGUCCGUACUGGUGUUA
protein 1 (MCL1)
D57 Nicastrin (Nct) AAGGGCAAGTTTCCCGTGCAG
D58 NuMA Z11583 3988-4010 aaggcgtggcaggagaagttc
D59 Nup153 NM_005124 2593-2615 aaggcagactctaccaaatgt
D60 Origin recognition AAUGGUAGCCACAUCCGGUGU
complex protein 6 (Orc6)
D61 Origin recognition AAGATTGGACAGCAGGUCGAC
complex protein 6 (Orc6)
D62 Polo-like Kinase1 NM_005030 181-203 AAGGGCGGCTTTGCCAAGTGC
(hPlk1)
D63 Protein Kinase 931-949 AAGATCAAGTTTTGCCAATG
D64 Receptor (PKR) hRad9 U53174 232-252 AAGUCUUUCCUGUCUGUCUUU

D65 Rad17 AACAGACUGGGUUGACCCAUC

Allele Biotech-Introducing Cost Effectiveness to Research

Box 5| Product List Continued

Cat. No. Gene (Ref) Accession Position Gene Target

ABP-Ri-VAsi-D## # from (Comments)
ATG
D66 Signalling HSU73377 677-697 tcctacttggttcggtacatggg
Adapter/scaffold
protein (h/m Shc)
D67 p66 ShcA HSU73377 236-256 CGGAATGAGTCTCTGTCATCGTC

D68 Sphingosine kinase 1 70 nt AAGAGCUGCAAGGCCUUGCCC

(hSK1) downstream
of start
codon
D69 Steroid receptor CCUCAGGGCAGAGAACCAUCUTT
coactivator (SRC-1)
D70 ß-tubulin AF312873 3'-UTR GACAGAGCCAAGUGGACUCAC

D71 Tissue Factor (hTF) M16553 AAGCGCUUCAGGCACUACAAA

D72 Tissue Factor (hTF) M16553 AAGAAGCAGACGUACUUGGCA

D73 ß-transducin GUGGAAUUUGUGGAACAUCTT

repeat-containing
protein (ß-TrCP),
human
D74 TSG101 (a ubiquitin 413-433 AACCUCCAGUCUUCUCUCGUC
enzyme 2 variant
protein)
D75 VASP XM_009141 1087-1109 aaagaggaaatcattgaagcc
D76 vimentin NM_003380 346-368 aactacatcgacaaggtgcgc
(No silencing observed; 1,2)
D77 vimentin NM_003380 1145-1167 aataccaagacctgctcaatg

D78 Vimentin NM_003380 863-885 aagaatggtacaaatccaagt

D79 Vimentin NM_003380 1037-1059 aaatggaagagaactttgccg

D80 vinculin, mouse L18880 2923-2945 aagcggattagaaccaatctc

D81 zyxin, mouse X99063 1357-1379 aaagcctaccacccacagtgc

F or Research Use Only. Not for Diagnostic or Therapeutic Use.

Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of
another product. Any use of this product other than the permitted use without the express written authorization of Allele Biotech is strictly
prohibited

Allele Biotech-Introducing Cost Effectiveness to Research